ArticleHealth science reports2026
A Theoretical Model for the Treatment of Androgenetic Alopecia Using the STEAP3 Protein, and the Genetic Challenges of Treating AGA.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Androgenetic alopecia (AGA) is a prevalent condition. The treatment methods currently available for this condition have limited potential (minoxidil) and side effects with long-term therapy that affect the physiology of the male population (5α-reductase inhibitors). In recent years, there has been a considerable expansion in knowledge about the etiology of AGA, while current treatment methods appear to be outdated in light of new findings. Methods: A review of the latest publications on androgenetic alopecia concerning its etiology and genetics was conducted, with the aim of examining the molecular pathways associated with mutations in the following genes: The following genes were found to be implicated: AR (WNT/β-catenin pathway), EDA2R (WNT/β-catenin and proapoptotic pathways), HDAC9 (Treg pathway), PAX1 and FOXA2 (development pathways). This facilitated the development of a theoretical model for the treatment of AGA using the STEAP3 protein. Results: A theoretical model of AGA therapy has been designed using the STEAP3 protein to activate the inhibited WNT/β-catenin pathway as a result of mutations in the AR and EDA2R genes. STEAP3 catalyses the conversion of Fe Conclusion: It is hypothesised that STEAP3-based therapy has the potential to become an effective treatment for AGA, acting on the underlying cause of the disease (determined by the mutations described). It should be noted that all analyses presented in the following text constitute a theoretical model of AGA treatment using STEAP3 protein and its derivatives, and are not supported by laboratory and clinical studies. Nevertheless, they serve as an introduction to further in vitro, in vivo, and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.